普瑞巴林治疗糖尿病性周围神经痛的治疗效果与安全性的Meta分析被引量：6

Effects and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathic Pain:Meta-Analysis of Randomized Controlled Trials

原文传递

导出

摘要目的评价普瑞巴林治疗糖尿病性周围神经痛的有效性和安全性。方法采用循证医学的文献分析评价方法,计算机检索Cochrane图书馆、MEDLINE、EMbase、PUBMED、中国科技期刊全文数据库、维普电子期刊全文数据库、万方数据库等文献数据库以及手工检索相关会议的论文集,采用RevMan5.1进行Meta分析。结果纳入研究8项,共1 596例患者。Meta分析结果显示,普瑞巴林组的反应有效率[OR=2.81,95%CI(2.03,3.89),P<0.000 01]、患者总体印象变化比例[OR=2.94,95%CI(2.05,4.20),P<0.000 01]和临床总体印象变化比例[OR=2.42,95%CI(1.53,3.82),P=0.000 1]明显高于安慰剂组,研究终点疼痛评分明显低于安慰剂组[WMD=-1.08,95%CI(-1.52,-0.63),P<0.000 01]。亚组分析显示,600 mg·d-1组的治疗效果优于300 mg·d-1组。不良反应发生率高于安慰剂组[OR=5.71,95%CI(4.05,6.60),P<0.000 01],为轻到中度,可耐受。普瑞巴林与含5%利多卡因药膏、度洛西汀相比,治疗效果相似。不良反应方面,普瑞巴林较5%利多卡因药膏发生率高,与度洛西汀相似。结论普瑞巴林治疗糖尿病性周围神经痛效果显著,安全性好。 OBJECTIVE To compare the effects and safety of pregabalin for the treatment of diabetic peripheral neuropathic pain. METHODS Cochrane library, MEDLINE, Embase, PUBMED, CNKI, VIP database, Wan fang database and paper manual of related conferences were searched. The Meta-analysis was performed by RevMan 5.1. RESULTS Eight studies were included （n = 1 596）. The analysis indicated that there were significant differences between pregabaliu and placebo in respondent rate[ OR=2. 81, 95% CI（ 2. 03,3.89） ,P 〈 0. 000 011, endpoint mean pain scores [ WMD = - 1.08,95% CI （ - 1.52, -0. 63 ）, P 〈 0. 000 01 ], pa- tient global impression of change [ OR = 2. 94,95% CI （2. 05,4. 20 ）, P 〈 0. 000 01] and clinical global impression of change [ OR = 2. 42,95% CI（1. 53,3. 82） ,P =0. 000 11. The subgroup analysis showed that the efficacy treated with 600 mg·d-l is superior to that with 300 mg· d -2. The adverse event rate is higher treated with pregabalin than that with placebo [ OR = 5.71,95% CI （4. 05,6. 60） , P 〈 0. 000 01 ]. Compared with 5% lidocaine（Lignocaine） medicated plaster, the efficacy of pregabalin is similar while adverse event rate is higher. There were similar efficacy and safety between pregabalin and duloxetine. CONCLUSION With superior effects, similar safety, pregabalin may be preferred for the patients with diabetic peripheral neuropathic pain.

作者杨丽娟林平梁健华甄健存

机构地区北京积水潭医院

出处《中国药学杂志》 CAS CSCD 北大核心 2013年第21期1881-1885,共5页 Chinese Pharmaceutical Journal

关键词普瑞巴林糖尿病性周围神经痛随机对照试验 META分析 pregabalin diabetic peripheral neuropathic pain randomized controlled trials Meta-analysis

分类号 R96 [医药卫生—药理学]

引文网络
相关文献

参考文献1

1孙德海,纪春梅,马玲,姜长林.普瑞巴林用于糖尿病痛性神经病变的疗效和安全性[J].中国新药杂志,2011,20(14):1302-1304. 被引量：7

二级参考文献12

1GORE M, BRANDENBURG NA, HOFFMAN DL, et al. Burden of illness in painful diabetic peripheral neuropathy : the patients' perspectives [ J ]. Pain,2006,7 ( 12 ) : 892 - 900.
2SILLS GJ. The mechanisms of action of gahapentin and pregaba- lin [ J ]. Curr Opin Pharmacol,2006,6 ( 1 ) : 108 - 113.
3BIAN F, LI Z, OFFORD J,et al. Calcium channel alpha2-deha type 1 subunit is themajorbinding protein for pregabalin in neoco- rtex, hippocampus, amygdala, and spinal cord: an cx vivo auto radiographic study in alpha2-delta type 1 genetically modified mice[J].Brain Res, 2006, 1075(1): 68-80.
4JOSHI I, TAYLOR CP. Pregabalin action at a model synapse: binding to presynaptic calcium channel alpha2-deha subunit re- duces in mice [ J ]. Eur J Pharmacol, 2006 553(1 -3) : 82 -88.
5MCCLELLAND D, EVANS RM, BARKWORTH L,et al. A study comparing the actions of gabapentin and pregabalin on the electrophysiological properties of cultured DRG neurones from neonatal rats [ J ]. BMC Pharmacol, 2004, 4 : 14.
6INDMARCH I, TRICK L, RIDOUT F. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of he cognitive and psychomotor profile of pregabalin in healthy volun- teers [ J ]. Psychopharmacology ( Berl), 2005, 183 ( 2 ) : 133 - 143.
7RICHTER RW, PORTENOY R, SHARMA U,et al. Relief of painful diabetic peripheral Neuropathy with pregabalin: a ran- domized, placebo-controlled trial [ J ]. Pain, 2005, 6 ( 4 ) : 253 - 260.
8CROFFORD LJ, ROWBOTHAM MC,MEASE PJ,et al. Pregaba- lin for the treatment of fibromyalgia syndrome: results of a ran- domized, double-blind, placebo-controlled trial [ J ]. Arthritis Rheum, 2005, 52(4): 1264-1273.
9TARRIDE JE, GORDON A, VERA-LLONCH M,et al. Cost ef- fectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective [ J ]. Clin Ther, 2006, 28 (11) : 1922 -1934.
10FREYNHAGEN R, BUSCHE P, KONRAD C,et al. Effective- ness and time to onset of pregabalin in patients with neuropathic pain[ J]. Schmerz, 2006, 20(4): 285- 288, 290- 292.